Shingrix, a two-dose, non-live vaccine used to prevent shingles in older adults, gives strong, long-lasting protection, including against the lingering nerve pain and eye damage that can follow, though weaker with immune suppression. A few days of arm pain, tiredness or fever are common; a rare nerve disorder appears very slightly more often after the first dose. Possible lower dementia and heart attack risk is still being tested. (Full Review)

Protocol

Standard dose (label and ACIP)

Two 0.5 mL intramuscular injections

Deltoid (upper-arm muscle), 2–6 months apart, adults ≥50

Shortened schedule (immunocompromised)

Second dose 1–2 months after the first

Adults ≥19 who are or will be immunosuppressed

Single versus split dosing

Full two-dose series

Full 0.5 mL dose as one injection; one dose 56.9% vs 70.1% effectiveness for two

Time to effect

Shingles protection

1 month after dose 2

Protection builds after the second dose; trial efficacy measured from this point

Dementia & cardiovascular effects

Over years

Any dementia or cardiovascular effects, if real, would emerge over years

Benefits

Medium: Prevention of shingles; prevention of postherpetic neuralgia and eye involvement; lower risk of dementia; fewer heart attacks, strokes and heart failure events; slower progression of chronic kidney disease; fewer COVID-19 diagnoses and hospitalizations

Low: Lower all-cause mortality

Speculative: Slower biological aging

Contraindications

History of severe allergic reaction (e.g., anaphylaxis) to any vaccine component or a previous dose

Current acute shingles episode

Pregnancy

Moderate or severe acute illness, with or without fever

Autologous (own-cell) stem cell transplant recipients <3 months and allogeneic (donor-cell) recipients <6 months after transplant

Solid organ transplant recipients <6 months after transplant or with recent rejection

Adults who have never had chickenpox nor varicella vaccination

Key Interactions

Anti-B-cell therapies (rituximab, ocrelizumab): Monitor/timing

Other immunosuppressants (abatacept, high-dose glucocorticoids, chemotherapy): Caution

BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib): Caution

JAK inhibitors (tofacitinib, baricitinib, upadacitinib): Monitor

Herpes antivirals (acyclovir, valacyclovir, famciclovir): No interaction

Anticoagulants (warfarin, apixaban, rivaroxaban): Caution (theoretical)

Over-the-counter analgesics and antipyretics (acetaminophen, ibuprofen, naproxen): Avoid prophylactic use (theoretical for adults)

Other vaccines (influenza, pneumococcal, Tdap, COVID-19): No interference

AS01-adjuvanted RSV vaccine (Arexvy): Monitor

Recent live vaccines (Zostavax, varicella vaccine): Caution (theoretical)

Supplements: Caution (theoretical)

Risk & Side Effects

High: Short-lived injection-site and whole-body reactions

Medium: Guillain-Barré syndrome; gout flares

Low: Fainting after injection; flares of autoimmune disease; allergic reactions; shingles shortly after dose 1

Speculative: Unknown effects in pregnancy

Monitoring

Marker	Target	Why
VZV IgG antibody blood test	No established target; track documented history of chickenpox or shingles instead	Safety check: a negative result in an immunocompromised adult without varicella history changes use
Anti-gE IgG antibody concentration	No established target; track completion of the two-dose series instead	Marker the vaccine is expected to change
gE-specific CD4+ T-cell frequency	No established target; track freedom from shingles instead	Marker the vaccine is expected to change

Cadence: No laboratory testing required before the first dose; symptoms tracked for 7 days and neurological symptoms for 42 days after each dose, autoimmune disease activity for 12 weeks in people with such conditions; no repeat laboratory testing after the series

Qualitative Assessment

Severity and duration of arm pain, fatigue and fever after each dose (expected to settle within 2–3 days)
Any tingling, numbness or weakness spreading from the hands or feet within 42 days
Autoimmune or gout symptom activity in the 12 weeks after each dose
Occurrence of any shingles-like rash or nerve pain in the following years
Subjective cognitive clarity and memory over the long term (no short-term change is expected)

Shingrix for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment